|Bid||200.00 x 800|
|Ask||221.18 x 800|
|Day's range||216.69 - 219.78|
|52-week range||179.59 - 222.42|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||22.57|
|Earnings date||14 Feb 2024 - 19 Feb 2024|
|Forward dividend & yield||2.88 (1.32%)|
|Ex-dividend date||07 Nov 2023|
|1y target est||241.54|
Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.
Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy's outreach laboratory business. Labcorp also now manages Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply chain services and laboratory support.